adoptive immunotherapy

(redirected from adoptive transfer)
Also found in: Dictionary, Medical.
Related to adoptive transfer: Flow cytometry, transgenic

adoptive immunotherapy

[ə¦däp·tiv ‚im·yə·nō′ther·ə·pē]
(immunology)
The transfer of immunologically competent white blood cells or their precursors into the host.
Mentioned in ?
References in periodicals archive ?
Patients received IL-2 in vivo following adoptive transfer. The AML patient died of relapse (day +80), while the two ALL patients died of transplant-related complications.
Figure 6: Clinical effect of adoptive transfer of pDCs from mice treated with CpG-A or PBS on EAE.
Even though we detected hematopoietic anomalies in the myeloid population of [HDC.sup.-/-] mice, these cells were not involved in the protective response, as demonstrated by adoptive transfer. Although neutrophils express the same markers as IMCs, the protection against diabetes in HDC-deficient mice cannot be ascribed to an increase of this population among the [CD11b.sup.+][Gr-1.sup.+] subset since neutrophil depletion has been shown to inhibit type-1 diabetes development in NOD mice [36].
We used data from individual animals in all experiments; however, for adoptive transfer experiments, data were concatenated due to the low number of gated events for T-cell subsets.
One implication is that future immune-based therapies for cancers and other diseases might get effective results from adoptive transfer of small numbers of individual T cells.
Adoptive Transfer. Lymph nodes and spleens were collected from TCR transgenic BALB/c mice from estimate one donor to four recipients [21], homogenized in RPMI-1640 media, and passed over nylon mesh.
After adoptive transfer, the mean diabetes-free time in NOD/scid mice treated with vehicle (n = 8), ATRA (n = 7), exendin-4 (n = 9), and ATRA plus exendin-4 (n = 6) was 6.5, 8.0, 7.6, and 11.2 weeks, respectively.
Immunodeficient mice exhibit blunted vascular hypertrophy in response to Ang II [12] and adoptive transfer of Tregs prevents Ang II-induced vascular dysfunction [15].
Recent preclinical and clinical studies provide evidence that adoptive transfer of in vitro activated T cells can results in significant antitumour responses in vivo upon acquisition of certain survival and homing properties during in vitro activation.
host (GvH) disease and graft rejection; cell therapy to prevent leukemia relapse; modalities to improve immune reconstitution after transplantation; clinical studies on boosting thymus output or using adoptive transfer of immunity against infectious agents or malignant cells; and new approaches to induce immune tolerance towards organ transplantation by hematopoietic stem cell transplantation.
In vitro studies and in vivo adoptive transfer experiments revealed that CD4+CD25+ T cells from GM-CSFtreated mice could suppress effector T cell response and T1D.
Consequently, it has become possible to create immune recognition of cancer antigens through immunization and through adoptive transfer of antitumor lymphocytes into a lymphodepleted host.